Related Experiment Video
Updated: Jul 16, 2026
A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System
Published on: April 6, 2021
Anti-SARS-CoV-2 IgG and IgM detection with a GMR based LFIA system
Qiaoge Bayin1, Lei Huang2, Chunhui Ren1
1School of Information and Communication Engineering, University of Electronic Science and Technology of China, Chengdu, 611731, PR China.
Insights
This study presents a novel lateral flow immunoassay using superparamagnetic nanoparticles and a giant magnetoresistance system for rapid, simultaneous detection of IgM and IgG antibodies against SARS-CoV-2. This cost-effective method aids in assessing COVID-19 infection status.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Immunodiagnostics
Background:
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused a global health crisis, necessitating accurate and efficient diagnostic tools.
- Understanding a patient's infection history and degree of infection through antibody testing is crucial for public health policy and patient management.
Purpose of the Study:
- To develop a simultaneous quantitative detection method for anti-SARS-CoV-2 immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies.
- To create a cost-effective, time-efficient, and user-friendly diagnostic system for COVID-19 antibody testing.
Main Methods:
- Preparation of superparamagnetic nanoparticles (SMNPs) using a co-precipitation method.
- Development of a lateral flow immunoassay (LFIA) utilizing SMNPs.
- Integration of a giant magnetoresistance (GMR) sensing system with Internet of Medical Things (IoMT) capabilities for data transmission via Bluetooth.
Main Results:
- Successfully prepared well-dispersed SMNPs with an average diameter of 68 nm.
- Demonstrated simultaneous quantitative detection of anti-SARS-CoV-2 IgM and IgG.
- The GMR-based LFIA system showed cost-effectiveness, time-efficiency, and ease of operation.
Conclusions:
- The proposed SMNP-based LFIA integrated with a GMR sensing system offers a promising approach for rapid and simultaneous COVID-19 antibody detection.
- This technology can support medical staff in analyzing infection status and maintaining patient records.
- The IoMT-enabled GMR system facilitates accessible medical data transmission for improved healthcare management.
Abstract:
Since December 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused millions of deaths and seriously threatened the safety of human life; indeed, this situation is worsening and many people are infected with the new coronavirus every day. Therefore, it is very important to understand patients' degree of infection and infection history through antibody testing. Such information is useful also for the government and hospitals to formulate reasonable prevention policies and treatment plans. In this paper, we develop a lateral flow immunoassay (LFIA) method based on superparamagnetic nanoparticles (SMNPs) and a giant magnetoresistance (GMR) sensing system for the simultaneously quantitative detection of anti-SARS-CoV-2 immunoglobulin M (IgM) and G (IgG). A simple and time-effective co-precipitation method was utilized to prepare the SMNPs, which have good dispersibility and magnetic property, with an average diameter of 68 nm. The Internet of Medical Things-supported GMR could transmit medical data to a smartphone through the Bluetooth protocol, making patient information available for medical staff. The proposed GMR system, based on SMNP-supported LFIA, has an outstanding advantage in cost-effectiveness and time-efficiency, and is easy to operate. We believe that the suggested GMR based LFIA system will be very useful for medical staff to analyze and to preserve as a record of infection in COVID-19 patients.
